Pediatrix Medical (MD) Group announced that its Board of Directors has authorized a share repurchase program of up to $250M of the Company’s outstanding common stock. “In view of our strong cash flow, current and forecasted cash balances and relatively low debt levels, our Board has authorized a $250M share repurchase program, which we plan to use opportunistically,” said Mark S. Ordan, Chair of the Board and CEO. The timing and actual number of shares repurchased will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements, and alternative investment opportunities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical price target raised to $16.50 from $16 at UBS
- Pediatrix Medical sees FY25 adjusted EBITDA $245M-$255M
- Pediatrix Medical reports Q2 adjusted EPS 53c, consensus 42c
- Pediatrix Medical Group, Inc. (MD) Q2 Earnings Cheat Sheet
- Cautious Optimism: Evaluating Pediatrix Medical Group Amid Shifting Birth Trends